Health Care Reform that Works for All

Single-payer schemes and proposals to incrementally give government more control and power over health care spending and decisions would harm access and erode quality. Policy initiatives that promote competition, and encourage investment in new drugs, treatments and innovative solutions for delivering health care are the type of reforms that will make the system more responsive to America’s health care consumers.

March 16th, 2022 by

NEWS For Immediate Release Washington, D.C. – Today, the Senate Finance Committee is holding a hearing on prescription drug prices and possible solutions to lower costs, including price controls. Small Business & Entrepreneurship Council (SBE Council) president Karen Kerrigan issued the following statement about possible legislative efforts to impose price controls on this critical American […]

February 1st, 2022 by

In a February 1 Op-Ed in Real Clear Health, SBE Council president & CEO Karen Kerrigan and United States Hispanic Chamber of Commerce (USHCC) president & CEO Ramiro Cavazos lay out the policy priorities of small business owners as they work to survive and recover during this  uncertain pandemic economy.  As they note in the […]

January 13th, 2022 by

January 13, 2022 Dear Members of Congress: As America’s small business owners continue to navigate a host of challenges and work to stabilize their firms and recover from the effects of the COVID-19 pandemic, we believe that Congress must focus on policy solutions that restore their vibrancy and growth. Our national and local economies depend […]

December 20th, 2021 by

For Immediate Release December 20, 2021 Washington, D.C. – Today, the Small Business & Entrepreneurship Council (SBE Council) and the United States Hispanic Chamber of Commerce (USHCC) released the results of a poll examining the top policy concerns among the small business community and highlighting the need for Congress to focus on policies that aid […]

November 21st, 2021 by

In a Op-ed, SBE Council president & CEO Karen Kerrigan details one of the many problems with the “Build Back Better Act.”  Specifically, the price controls in the legislation would greatly undermine U.S. investment, innovation and access to new life-saving drugs. Kerrigan writes: “The impact on business would be enormous. An analysis by the […]

September 24th, 2021 by

TO THE MEMBERS OF THE U.S. HOUSE OF REPRESENTATIVES: We, the undersigned organizations, represent the interests of every sector and segment of the business community and together unequivocally oppose H.R. 3, the “Lower Drug Costs Now Act of 2019.” Promises to pass along government price controls to the employer-sponsored market do not change our fervent […]

September 13th, 2021 by

  The Honorable Chuck Schumer Majority Leader United States Senate Washington, DC 20510 The Honorable Mitch McConnell Republican Leader United States Senate Washington, DC 20510 The Honorable Nancy Pelosi Speaker United States House of Representatives Washington, DC 20515 The Honorable Kevin McCarthy Republican Leader United States House of Representatives Washington, DC 20515 Dear Leader Schumer, […]

September 10th, 2021 by

by Raymond J. Keating – Regulations – including price controls – always fall heaviest on smaller, entrepreneurial enterprises. That is very much the case in the biopharmaceutical industry. Price controls on prescription drugs would undermine entrepreneurship and private investment in the industry, and therefore, would undermine the creation of new and improved drugs, medicines and […]

September 10th, 2021 by

Dear Member of Congress: A few rogue “employer groups” who do not represent the interest of their member companies or the business community are pushing for price controls on prescription drugs, punitive taxes on pharmaceutical companies, and more government meddling in our health care system. Millions of small to mid-size companies across the United States […]

September 1st, 2021 by

Executive Order on “Competition” Would Damage Innovation, Endanger Health Consumers by RAYMOND J. KEATING – I’ve said it before, and I’ll say it again: I’m always bewildered by the political attacks on pharmaceutical companies. After all, these businesses produce medicines, drugs and vaccines that improve and save lives. Why attack and undermine such worthy endeavors? […]

News and Media Releases